Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
Spencer G. Van Decar, Elizabeth L. Carpenter, Alexandra M. Adams, Robert C. Chick, Guy T. Clifton, Alex Stojadinovic, Timothy J. Vreeland, Franklin A. Valdera, Ankur Tiwari, Anne E. O'Shea, Patrick M. McCarthy, Diane F. Hale, Phillip M.Kemp Bohan, Annelies T. Hickerson, Jessica L. Cindass, John Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser ShaheenXianzhong Yu, Thomas Wagner, Mark B. Faries, George E. Peoples
Dive into the research topics of 'Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial'. Together they form a unique fingerprint.